Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus

The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB 1 cannabinoid receptors. The hypothesis of the present work was that CB 1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuroscience 2005, Vol.133 (1), p.305-313
Hauptverfasser: Freiman, I., Szabo, B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 313
container_issue 1
container_start_page 305
container_title Neuroscience
container_volume 133
creator Freiman, I.
Szabo, B.
description The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB 1 cannabinoid receptors. The hypothesis of the present work was that CB 1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that their activation leads to presynaptic modulation of neurotransmission between these axons and globus pallidus neurons. Patch-clamp studies were carried out on oblique-sagittal mouse brain slices. The subthalamic nucleus was stimulated electrically and the resulting excitatory postsynaptic currents (EPSCs) were recorded in globus pallidus neurons. The mixed CB 1/CB 2 receptor agonist R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate (WIN55212-2; 3×10 −7 M) had no effect on EPSCs. WIN55212-2 (10 −5 M) decreased the amplitude of EPSCs by 44±8%. The inhibition by WIN55212-2 (10 −5 M) was prevented by the CB 1 antagonist N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide (10 −6 M). WIN55212-2 (10 −5 M) did not change the amplitude of spontaneous EPSCs (sEPSCs) recorded in globus pallidus neurons but lowered their frequency. Moreover, WIN55212-2 (10 −5 M) had no effect on currents elicited by direct activation of postsynaptic receptors on globus pallidus neurons by glutamate (10 −3 M) ejected from a pipette. In a final series of experiments, the firing of subthalamic nucleus neurons was recorded; WIN55212-2 (10 −5 M) did not change the firing of these neurons. The results show that activation of CB 1 receptors inhibits glutamatergic neurotransmission between the subthalamic nucleus and the globus pallidus. Lack of effect of cannabinoids on the amplitude of sEPSCs and on currents evoked by direct stimulation of postsynaptic glutamate receptors indicates that the mechanism is presynaptic inhibition of glutamate release from axon terminals. Cannabinoids seem to act preferentially presynaptically: in contrast to their action on axon terminals, they have no effect on somadendritic receptors regulating firing rate. Cannabinoids elicit catalepsy in vivo. The observed inhibition of glutamatergic neurotransmission in the globus pallidus would favor catalepsy.
doi_str_mv 10.1016/j.neuroscience.2005.01.058
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67831634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306452205001739</els_id><sourcerecordid>17198415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-9559136bbec5483d1c1661b380f24909b66a0a35369872ec815925bff93703703</originalsourceid><addsrcrecordid>eNqNkV9rFDEUxYModlv9CjII-jZjMvkziW-yai0U-lKfQ5K5Y7NkM2uSUfvtm-0O1DcNF0K4v5tzOQehtwR3BBPxYddFWNKcnYfooOsx5h0mHebyGdoQOdB24Iw9RxtMsWgZ7_szdJ7zDtfDGX2JzgiXigreb5DfmhiN9XH2Y25GOCTIuYE_zhdT5nTfPEqVZGLe-5z9HBsL5TdAbModNHmx5c4Es_euiYsLsOTGxPGx9yPMtj4PJgQ_LvkVejGZkOH1el-g71-_3G6_tdc3l1fbT9etY1SVVnGuCBXWguNM0pE4IgSxVOKpZworK4TBhnIqlBx6cJJw1XM7TYoO-FgX6P3p30Oafy6Qi66LOwjBRJiXrMUgKRGU_RMkA1GSEV7BjyfQVdNzgkkfkt-bdK8J1sdE9E7_nYg-JqIx0TWROvxmVVnsHsan0TWCCrxbAZOdCVO12vn8xAnJMOekcp9PHFTzfnlIepUbfQJX9Dj7_9nnAWqwsfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17198415</pqid></control><display><type>article</type><title>Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Freiman, I. ; Szabo, B.</creator><creatorcontrib>Freiman, I. ; Szabo, B.</creatorcontrib><description>The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB 1 cannabinoid receptors. The hypothesis of the present work was that CB 1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that their activation leads to presynaptic modulation of neurotransmission between these axons and globus pallidus neurons. Patch-clamp studies were carried out on oblique-sagittal mouse brain slices. The subthalamic nucleus was stimulated electrically and the resulting excitatory postsynaptic currents (EPSCs) were recorded in globus pallidus neurons. The mixed CB 1/CB 2 receptor agonist R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate (WIN55212-2; 3×10 −7 M) had no effect on EPSCs. WIN55212-2 (10 −5 M) decreased the amplitude of EPSCs by 44±8%. The inhibition by WIN55212-2 (10 −5 M) was prevented by the CB 1 antagonist N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide (10 −6 M). WIN55212-2 (10 −5 M) did not change the amplitude of spontaneous EPSCs (sEPSCs) recorded in globus pallidus neurons but lowered their frequency. Moreover, WIN55212-2 (10 −5 M) had no effect on currents elicited by direct activation of postsynaptic receptors on globus pallidus neurons by glutamate (10 −3 M) ejected from a pipette. In a final series of experiments, the firing of subthalamic nucleus neurons was recorded; WIN55212-2 (10 −5 M) did not change the firing of these neurons. The results show that activation of CB 1 receptors inhibits glutamatergic neurotransmission between the subthalamic nucleus and the globus pallidus. Lack of effect of cannabinoids on the amplitude of sEPSCs and on currents evoked by direct stimulation of postsynaptic glutamate receptors indicates that the mechanism is presynaptic inhibition of glutamate release from axon terminals. Cannabinoids seem to act preferentially presynaptically: in contrast to their action on axon terminals, they have no effect on somadendritic receptors regulating firing rate. Cannabinoids elicit catalepsy in vivo. The observed inhibition of glutamatergic neurotransmission in the globus pallidus would favor catalepsy.</description><identifier>ISSN: 0306-4522</identifier><identifier>EISSN: 1873-7544</identifier><identifier>DOI: 10.1016/j.neuroscience.2005.01.058</identifier><identifier>PMID: 15893652</identifier><identifier>CODEN: NRSCDN</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; basal ganglia ; Benzoxazines ; Biological and medical sciences ; Camphanes - pharmacology ; Cannabinoids - agonists ; Cannabinoids - pharmacology ; catalepsy ; CB 1 cannabinoid receptor ; Dendrites - drug effects ; Electrophysiology ; EPSC ; Excitatory Postsynaptic Potentials - drug effects ; Globus Pallidus - cytology ; Globus Pallidus - drug effects ; Medical sciences ; Mice ; Morpholines - pharmacology ; Naphthalenes - pharmacology ; Neural Pathways - cytology ; Neural Pathways - drug effects ; Neurons - drug effects ; Neurons - physiology ; Neuropharmacology ; patch-clamp ; Patch-Clamp Techniques ; Pharmacology. Drug treatments ; Piperidines - pharmacology ; presynaptic inhibition ; Psychodysleptics: hallucinogen ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Pyrazoles - pharmacology ; Receptor, Cannabinoid, CB1 - drug effects ; Rimonabant ; Subthalamic Nucleus - cytology ; Subthalamic Nucleus - drug effects ; Synaptic Transmission - drug effects</subject><ispartof>Neuroscience, 2005, Vol.133 (1), p.305-313</ispartof><rights>2005 IBRO</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-9559136bbec5483d1c1661b380f24909b66a0a35369872ec815925bff93703703</citedby><cites>FETCH-LOGICAL-c439t-9559136bbec5483d1c1661b380f24909b66a0a35369872ec815925bff93703703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0306452205001739$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16840551$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15893652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freiman, I.</creatorcontrib><creatorcontrib>Szabo, B.</creatorcontrib><title>Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus</title><title>Neuroscience</title><addtitle>Neuroscience</addtitle><description>The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB 1 cannabinoid receptors. The hypothesis of the present work was that CB 1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that their activation leads to presynaptic modulation of neurotransmission between these axons and globus pallidus neurons. Patch-clamp studies were carried out on oblique-sagittal mouse brain slices. The subthalamic nucleus was stimulated electrically and the resulting excitatory postsynaptic currents (EPSCs) were recorded in globus pallidus neurons. The mixed CB 1/CB 2 receptor agonist R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate (WIN55212-2; 3×10 −7 M) had no effect on EPSCs. WIN55212-2 (10 −5 M) decreased the amplitude of EPSCs by 44±8%. The inhibition by WIN55212-2 (10 −5 M) was prevented by the CB 1 antagonist N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide (10 −6 M). WIN55212-2 (10 −5 M) did not change the amplitude of spontaneous EPSCs (sEPSCs) recorded in globus pallidus neurons but lowered their frequency. Moreover, WIN55212-2 (10 −5 M) had no effect on currents elicited by direct activation of postsynaptic receptors on globus pallidus neurons by glutamate (10 −3 M) ejected from a pipette. In a final series of experiments, the firing of subthalamic nucleus neurons was recorded; WIN55212-2 (10 −5 M) did not change the firing of these neurons. The results show that activation of CB 1 receptors inhibits glutamatergic neurotransmission between the subthalamic nucleus and the globus pallidus. Lack of effect of cannabinoids on the amplitude of sEPSCs and on currents evoked by direct stimulation of postsynaptic glutamate receptors indicates that the mechanism is presynaptic inhibition of glutamate release from axon terminals. Cannabinoids seem to act preferentially presynaptically: in contrast to their action on axon terminals, they have no effect on somadendritic receptors regulating firing rate. Cannabinoids elicit catalepsy in vivo. The observed inhibition of glutamatergic neurotransmission in the globus pallidus would favor catalepsy.</description><subject>Animals</subject><subject>basal ganglia</subject><subject>Benzoxazines</subject><subject>Biological and medical sciences</subject><subject>Camphanes - pharmacology</subject><subject>Cannabinoids - agonists</subject><subject>Cannabinoids - pharmacology</subject><subject>catalepsy</subject><subject>CB 1 cannabinoid receptor</subject><subject>Dendrites - drug effects</subject><subject>Electrophysiology</subject><subject>EPSC</subject><subject>Excitatory Postsynaptic Potentials - drug effects</subject><subject>Globus Pallidus - cytology</subject><subject>Globus Pallidus - drug effects</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Morpholines - pharmacology</subject><subject>Naphthalenes - pharmacology</subject><subject>Neural Pathways - cytology</subject><subject>Neural Pathways - drug effects</subject><subject>Neurons - drug effects</subject><subject>Neurons - physiology</subject><subject>Neuropharmacology</subject><subject>patch-clamp</subject><subject>Patch-Clamp Techniques</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - pharmacology</subject><subject>presynaptic inhibition</subject><subject>Psychodysleptics: hallucinogen</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Pyrazoles - pharmacology</subject><subject>Receptor, Cannabinoid, CB1 - drug effects</subject><subject>Rimonabant</subject><subject>Subthalamic Nucleus - cytology</subject><subject>Subthalamic Nucleus - drug effects</subject><subject>Synaptic Transmission - drug effects</subject><issn>0306-4522</issn><issn>1873-7544</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV9rFDEUxYModlv9CjII-jZjMvkziW-yai0U-lKfQ5K5Y7NkM2uSUfvtm-0O1DcNF0K4v5tzOQehtwR3BBPxYddFWNKcnYfooOsx5h0mHebyGdoQOdB24Iw9RxtMsWgZ7_szdJ7zDtfDGX2JzgiXigreb5DfmhiN9XH2Y25GOCTIuYE_zhdT5nTfPEqVZGLe-5z9HBsL5TdAbModNHmx5c4Es_euiYsLsOTGxPGx9yPMtj4PJgQ_LvkVejGZkOH1el-g71-_3G6_tdc3l1fbT9etY1SVVnGuCBXWguNM0pE4IgSxVOKpZworK4TBhnIqlBx6cJJw1XM7TYoO-FgX6P3p30Oafy6Qi66LOwjBRJiXrMUgKRGU_RMkA1GSEV7BjyfQVdNzgkkfkt-bdK8J1sdE9E7_nYg-JqIx0TWROvxmVVnsHsan0TWCCrxbAZOdCVO12vn8xAnJMOekcp9PHFTzfnlIepUbfQJX9Dj7_9nnAWqwsfw</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>Freiman, I.</creator><creator>Szabo, B.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>2005</creationdate><title>Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus</title><author>Freiman, I. ; Szabo, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-9559136bbec5483d1c1661b380f24909b66a0a35369872ec815925bff93703703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>basal ganglia</topic><topic>Benzoxazines</topic><topic>Biological and medical sciences</topic><topic>Camphanes - pharmacology</topic><topic>Cannabinoids - agonists</topic><topic>Cannabinoids - pharmacology</topic><topic>catalepsy</topic><topic>CB 1 cannabinoid receptor</topic><topic>Dendrites - drug effects</topic><topic>Electrophysiology</topic><topic>EPSC</topic><topic>Excitatory Postsynaptic Potentials - drug effects</topic><topic>Globus Pallidus - cytology</topic><topic>Globus Pallidus - drug effects</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Morpholines - pharmacology</topic><topic>Naphthalenes - pharmacology</topic><topic>Neural Pathways - cytology</topic><topic>Neural Pathways - drug effects</topic><topic>Neurons - drug effects</topic><topic>Neurons - physiology</topic><topic>Neuropharmacology</topic><topic>patch-clamp</topic><topic>Patch-Clamp Techniques</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - pharmacology</topic><topic>presynaptic inhibition</topic><topic>Psychodysleptics: hallucinogen</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Pyrazoles - pharmacology</topic><topic>Receptor, Cannabinoid, CB1 - drug effects</topic><topic>Rimonabant</topic><topic>Subthalamic Nucleus - cytology</topic><topic>Subthalamic Nucleus - drug effects</topic><topic>Synaptic Transmission - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freiman, I.</creatorcontrib><creatorcontrib>Szabo, B.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freiman, I.</au><au>Szabo, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus</atitle><jtitle>Neuroscience</jtitle><addtitle>Neuroscience</addtitle><date>2005</date><risdate>2005</risdate><volume>133</volume><issue>1</issue><spage>305</spage><epage>313</epage><pages>305-313</pages><issn>0306-4522</issn><eissn>1873-7544</eissn><coden>NRSCDN</coden><abstract>The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB 1 cannabinoid receptors. The hypothesis of the present work was that CB 1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that their activation leads to presynaptic modulation of neurotransmission between these axons and globus pallidus neurons. Patch-clamp studies were carried out on oblique-sagittal mouse brain slices. The subthalamic nucleus was stimulated electrically and the resulting excitatory postsynaptic currents (EPSCs) were recorded in globus pallidus neurons. The mixed CB 1/CB 2 receptor agonist R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl)methanone mesylate (WIN55212-2; 3×10 −7 M) had no effect on EPSCs. WIN55212-2 (10 −5 M) decreased the amplitude of EPSCs by 44±8%. The inhibition by WIN55212-2 (10 −5 M) was prevented by the CB 1 antagonist N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide (10 −6 M). WIN55212-2 (10 −5 M) did not change the amplitude of spontaneous EPSCs (sEPSCs) recorded in globus pallidus neurons but lowered their frequency. Moreover, WIN55212-2 (10 −5 M) had no effect on currents elicited by direct activation of postsynaptic receptors on globus pallidus neurons by glutamate (10 −3 M) ejected from a pipette. In a final series of experiments, the firing of subthalamic nucleus neurons was recorded; WIN55212-2 (10 −5 M) did not change the firing of these neurons. The results show that activation of CB 1 receptors inhibits glutamatergic neurotransmission between the subthalamic nucleus and the globus pallidus. Lack of effect of cannabinoids on the amplitude of sEPSCs and on currents evoked by direct stimulation of postsynaptic glutamate receptors indicates that the mechanism is presynaptic inhibition of glutamate release from axon terminals. Cannabinoids seem to act preferentially presynaptically: in contrast to their action on axon terminals, they have no effect on somadendritic receptors regulating firing rate. Cannabinoids elicit catalepsy in vivo. The observed inhibition of glutamatergic neurotransmission in the globus pallidus would favor catalepsy.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15893652</pmid><doi>10.1016/j.neuroscience.2005.01.058</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0306-4522
ispartof Neuroscience, 2005, Vol.133 (1), p.305-313
issn 0306-4522
1873-7544
language eng
recordid cdi_proquest_miscellaneous_67831634
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
basal ganglia
Benzoxazines
Biological and medical sciences
Camphanes - pharmacology
Cannabinoids - agonists
Cannabinoids - pharmacology
catalepsy
CB 1 cannabinoid receptor
Dendrites - drug effects
Electrophysiology
EPSC
Excitatory Postsynaptic Potentials - drug effects
Globus Pallidus - cytology
Globus Pallidus - drug effects
Medical sciences
Mice
Morpholines - pharmacology
Naphthalenes - pharmacology
Neural Pathways - cytology
Neural Pathways - drug effects
Neurons - drug effects
Neurons - physiology
Neuropharmacology
patch-clamp
Patch-Clamp Techniques
Pharmacology. Drug treatments
Piperidines - pharmacology
presynaptic inhibition
Psychodysleptics: hallucinogen
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Pyrazoles - pharmacology
Receptor, Cannabinoid, CB1 - drug effects
Rimonabant
Subthalamic Nucleus - cytology
Subthalamic Nucleus - drug effects
Synaptic Transmission - drug effects
title Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T16%3A21%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cannabinoids%20depress%20excitatory%20neurotransmission%20between%20the%20subthalamic%20nucleus%20and%20the%20globus%20pallidus&rft.jtitle=Neuroscience&rft.au=Freiman,%20I.&rft.date=2005&rft.volume=133&rft.issue=1&rft.spage=305&rft.epage=313&rft.pages=305-313&rft.issn=0306-4522&rft.eissn=1873-7544&rft.coden=NRSCDN&rft_id=info:doi/10.1016/j.neuroscience.2005.01.058&rft_dat=%3Cproquest_cross%3E17198415%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17198415&rft_id=info:pmid/15893652&rft_els_id=S0306452205001739&rfr_iscdi=true